December 27, 2007 - Roswell Park Cancer Institute’s (RPCI) Cancer Center Support Grant (CCSG) will be renewed by the National Cancer Institute (NCI) for five years, following the receipt of the best CCSG score in its history.

RPCI has been an NCI-designated comprehensive cancer center, without interruption, since 1974, and was one of the three centers used by the NCI as a model for the 39 comprehensive cancer centers in existence today.

"The receipt of a superb score on the renewal of our NCI Core Grant is testament to the outstanding work of the Roswell Park team and affirms that we are committed to conducting innovative and pioneering research and providing exemplary patient care," said Donald L. Trump , M.D., FACP, President & CEO, RPCI. "These are the attributes of a world class cancer center and we are proud that the NCI has recognized the quality of our cancer programs and faculty."

To be designated a comprehensive cancer center by the National Cancer Institute, a cancer center must demonstrate depth and breadth of research activities in each of the three major areas of cancer research including basic; clinical; and prevention, control and population-based research, as well as maintain a strong body of interactive research that bridges these scientific areas.

In the area of clinical research, a comprehensive cancer center must initiate and conduct early phase, innovative clinical trials; and provide leadership and accrue patients to these trials. A center also must provide outreach, education and information on cancer to the community it serves.

The CCSG renewal is a multi-step competitive process. RPCI's renewal involved submitting a 1,100 page comprehensive grant application and an on-site visit in September 2007 from NCI peer-reviewers. After a thorough and rigorous review, RPCI's scores improved in more than 25 areas when compared to its last review in 2003 and are among the best scores the institute has ever received.

For more information:

Related Content

News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
Feature | Cardio-oncology | Dave Fornell

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat ...

Time May 13, 2016
News | Oncology Related Products

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy ...

Time May 06, 2016
Subscribe Now